Form 4: Vertex Pharmaceuticals Director Lloyd Carney Reports Acquisition and Disposal of Common Stock
SEC Form 4 Filing
Director Lloyd Carney reports acquiring 796 shares of Vertex Pharmaceuticals common stock and disposing of 7,115 shares on May 1, 2025.
Summary
- On May 1, 2025, Lloyd Carney, a director of Vertex Pharmaceuticals, reported acquiring 796 shares of common stock.
- The acquisition was related to a restricted stock unit award.
- Carney also disposed of 7,115 shares of common stock on the same day.
- Following these transactions, Carney beneficially owns 7,115 shares of Vertex Pharmaceuticals.
- The restricted stock unit award vests on the first anniversary of the grant date, subject to certain exceptions.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the actions of company leadership.
Stakeholder Impact
- Shareholders are informed about the stock transactions of a key company director.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of stock acquisition and disposal. |
| 05/05/2025 | Date of signature on the report. |
Keywords
Form 4, Beneficial Ownership, Stock Transaction, Vertex Pharmaceuticals, Director, Lloyd Carney, VRTX, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.